Abstract: The present invention relates to a pharmaceutical composition of a compound as shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer, or a crystal form thereof with a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody, and a kit thereof and the use thereof in the treatment of cancer diseases, wherein Y, P, W and Ar are as defined in the specification.

Abstract: A pharmaceutical composition and use of a multi-kinase inhibitor. The present invention relates to the technical field of medicines, and relates to the pharmaceutical composition and use of the multi-kinase inhibitor. The pharmaceutical composition comprises: (a) a compound represented by general formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a crystal form thereof, wherein P1, W1, Y1, and Ar in general formula (I) are as described herein; and (b) a paclitaxel drug. Variables in the general formula are as defined in the description. Studies have shown that the compound of general formula (I) or the pharmaceutically acceptable salt, stereoisomer or crystal form thereof in the present invention has a significant synergistic interaction with the paclitaxel drug in combination for treating cancers.

Abstract: The present invention belongs to the technical field of medicines, relates to novel use of a multi-kinase inhibitor, and particularly relates to a compound of general formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof for use in the treatment of biliary tract cancer, a pharmaceutical composition comprising the compound, a method for treating biliary tract cancer by using the compound, use of the compound in the treatment of biliary tract cancer, and use of the compound in the preparation of a medicament for treating biliary tract cancer. The variables in the general formula are defined in the specification. Research shows that the multi-kinase inhibitor compound of general formula (I) or the pharmaceutically acceptable salt, the stereoisomer and the crystal form thereof have a treatment effect on biliary tract cancer, and especially on cholangiocarcinoma, so that the compound of the present invention has huge clinical application potential.